Postnatal protein replacement was partially effective in animal models but not in human patients (Körber et al., 2020), whereas prenatal intra-amniotic administration of a recombinant EDA1 molecule to infants with XLHED resulted in normal sweat gland endowment and sweating ability, development of more teeth, and normalized function of salivary glands (Schneider et al., 2018; Körber et al., 2020) and, thus, showed the potential to permanently resolve the most relevant clinical problems associated with XLHED (Wohlfart et al., 2020). Here, EDA is linked to X-linked hypohidrotic ectodermal dysplasia.